Literature DB >> 25666893

Are androgen receptor variants a substitute for the full-length receptor?

Ji Lu1, Travis Van der Steen2, Donald J Tindall3.   

Abstract

Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25666893     DOI： 10.1038/nrurol.2015.13

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  68 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Authors:  Xi Yang; Zhiyong Guo; Feng Sun; Wei Li; Alan Alfano; Hermela Shimelis; Mingyuan Chen; Angela M H Brodie; Hegang Chen; Zhen Xiao; Timothy D Veenstra; Yun Qiu
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

3.  The androgen receptor gene mutations database: 2012 update.

Authors:  Bruce Gottlieb; Lenore K Beitel; Abbesha Nadarajah; Miltiadis Paliouras; Mark Trifiro
Journal:  Hum Mutat       Date:  2012-03-13       Impact factor: 4.878

4.  IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

Authors:  Maria Rosaria Cardillo; Flora Ippoliti
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

5.  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Authors:  Kush Dalal; Mani Roshan-Moniri; Aishwariya Sharma; Huifang Li; Fuqiang Ban; Mohamed Hessein; Michael Hsing; Kriti Singh; Eric LeBlanc; Scott Dehm; Emma S Tomlinson Guns; Artem Cherkasov; Paul S Rennie
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

8.  Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells.

Authors:  Matthias B Stope; Juliane Bradl; Stefanie Peters; Andreas Streitbörger; Martin Weiss; Uwe Zimmermann; Reinhard Walther; Christopher H Lillig; Martin Burchardt
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

9.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Authors:  Jae-Kyung Myung; Carmen A Banuelos; Javier Garcia Fernandez; Nasrin R Mawji; Jun Wang; Amy H Tien; Yu Chi Yang; Iran Tavakoli; Simon Haile; Kate Watt; Iain J McEwan; Stephen Plymate; Raymond J Andersen; Marianne D Sadar
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

10.  Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Authors:  Joanna L Gillis; Luke A Selth; Margaret M Centenera; Scott L Townley; Shihua Sun; Stephen R Plymate; Wayne D Tilley; Lisa M Butler
Journal:  Oncotarget       Date:  2013-05
View more
  55 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

Review 2.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

3.  Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.

Authors:  Yundong He; Ji Lu; Zhenqing Ye; Siyuan Hao; Liewei Wang; Manish Kohli; Donald J Tindall; Benyi Li; Runzhi Zhu; Liguo Wang; Haojie Huang
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

4.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 5.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

6.  Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Authors:  Yi Yin; Rui Li; Kangling Xu; Sentai Ding; Jeffrey Li; GuemHee Baek; Susmita G Ramanand; Sam Ding; Zhao Liu; Yunpeng Gao; Mohammed S Kanchwala; Xiangyi Li; Ryan Hutchinson; Xihui Liu; Solomon L Woldu; Chao Xing; Neil B Desai; Felix Y Feng; Sandeep Burma; Johann S de Bono; Scott M Dehm; Ram S Mani; Benjamin P C Chen; Ganesh V Raj
Journal:  Cancer Res       Date:  2017-07-28       Impact factor: 12.701

7.  Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Authors:  Fangfang Qu; Wanling Xie; Mari Nakabayashi; Haitao Zhang; Seong Ho Jeong; Xiaodong Wang; Kazumasa Komura; Christopher J Sweeney; Oliver Sartor; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

Review 8.  Emerging data on androgen receptor splice variants in prostate cancer.

Authors:  Subing Cao; Yang Zhan; Yan Dong
Journal:  Endocr Relat Cancer       Date:  2016-10-04       Impact factor: 5.678

9.  [AR-V7 as a predictive biomarker for prostate cancer-more than just prophecy].

Authors:  C Bernemann; L-M Krabbe
Journal:  Urologe A       Date:  2020-01       Impact factor: 0.639

Review 10.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.